IBA Proton Therapy

25/06/2026

🎉 We are excited to share that IBA will install 𝘁𝗵𝗲 𝗳𝗶𝗿𝘀𝘁 𝗽𝗿𝗼𝘁𝗼𝗻 𝘁𝗵𝗲𝗿𝗮𝗽𝘆 𝗰𝗲𝗻𝘁𝗲𝗿 𝗶𝗻 𝗕𝗿𝗮𝘇𝗶𝗹!
IBA Proton Therapy has signed a contract with the Fundação Severino Sombra (FUSVE), a non-profit philanthropic healthcare and educational institution responsible for the Universidade de Vassouras and Hospital Mário Kroeff, for the purchase of a Proteus®ONE system.
The initiative will establish Brazil’s first national proton therapy center, with a primary focus on 𝗽𝗲𝗱𝗶𝗮𝘁𝗿𝗶𝗰 𝗰𝗮𝗻𝗰𝗲𝗿 𝗰𝗮𝗿𝗲, 𝗶𝗻 𝗕𝗮𝗿𝗿𝗮 𝗱𝗮 𝗧𝗶𝗷𝘂𝗰𝗮, 𝗥𝗶𝗼 𝗱𝗲 𝗝𝗮𝗻𝗲𝗶𝗿𝗼. Developed in close scientific and technical partnership with the National Cancer Institute (INCA), the project also includes a roadmap for a second treatment room in the future. FUSVE expects to start treating patients during the first half of 𝟮𝟬𝟯𝟬.
Gustavo Oliveira do Amaral, President of FUSVE, commented: “𝘉𝘺 𝘣𝘳𝘪𝘯𝘨𝘪𝘯𝘨 𝘵𝘩𝘦 𝘧𝘪𝘳𝘴𝘵 𝘗𝘳𝘰𝘵𝘦𝘶𝘴®𝘖𝘕𝘌 𝘵𝘰 𝘉𝘳𝘢𝘻𝘪𝘭, 𝘸𝘦 𝘢𝘳𝘦 𝘵𝘢𝘬𝘪𝘯𝘨 𝘢 𝘩𝘪𝘴𝘵𝘰𝘳𝘪𝘤 𝘴𝘵𝘦𝘱 𝘪𝘯 𝘵𝘳𝘢𝘯𝘴𝘧𝘰𝘳𝘮𝘪𝘯𝘨 𝘤𝘢𝘯𝘤𝘦𝘳 𝘤𝘢𝘳𝘦 𝘪𝘯 𝘰𝘶𝘳 𝘤𝘰𝘶𝘯𝘵𝘳𝘺. 𝘞𝘦 𝘤𝘩𝘰𝘴𝘦 𝘐𝘉𝘈 𝘣𝘦𝘤𝘢𝘶𝘴𝘦 𝘸𝘦 𝘸𝘢𝘯𝘵𝘦𝘥 𝘢 𝘱𝘢𝘳𝘵𝘯𝘦𝘳, 𝘯𝘰𝘵 𝘫𝘶𝘴𝘵 𝘢 𝘴𝘶𝘱𝘱𝘭𝘪𝘦𝘳 — 𝘰𝘯𝘦 𝘸𝘪𝘵𝘩 𝘶𝘯𝘮𝘢𝘵𝘤𝘩𝘦𝘥 𝘨𝘭𝘰𝘣𝘢𝘭 𝘭𝘦𝘢𝘥𝘦𝘳𝘴𝘩𝘪𝘱, 𝘱𝘳𝘰𝘷𝘦𝘯 𝘤𝘭𝘪𝘯𝘪𝘤𝘢𝘭 𝘦𝘹𝘤𝘦𝘭𝘭𝘦𝘯𝘤𝘦, 𝘦𝘴𝘱𝘦𝘤𝘪𝘢𝘭𝘭𝘺 𝘪𝘯 𝘱𝘦𝘥𝘪𝘢𝘵𝘳𝘪𝘤𝘴, 𝘢𝘯𝘥 𝘢 𝘨𝘦𝘯𝘶𝘪𝘯𝘦 𝘤𝘰𝘮𝘮𝘪𝘵𝘮𝘦𝘯𝘵 𝘵𝘰 𝘴𝘶𝘱𝘱𝘰𝘳𝘵𝘪𝘯𝘨 𝘪𝘯𝘴𝘵𝘪𝘵𝘶𝘵𝘪𝘰𝘯𝘴 𝘭𝘪𝘬𝘦 𝘰𝘶𝘳𝘴. 𝘛𝘰𝘨𝘦𝘵𝘩𝘦𝘳, 𝘸𝘦 𝘸𝘪𝘭𝘭 𝘤𝘳𝘦𝘢𝘵𝘦 𝘢 𝘯𝘢𝘵𝘪𝘰𝘯𝘢𝘭 𝘢𝘯𝘥 𝘳𝘦𝘨𝘪𝘰𝘯𝘢𝘭 𝘳𝘦𝘧𝘦𝘳𝘦𝘯𝘤𝘦 𝘤𝘦𝘯𝘵𝘦𝘳 𝘵𝘩𝘢𝘵 𝘸𝘪𝘭𝘭 𝘪𝘯𝘴𝘱𝘪𝘳𝘦 𝘢𝘯𝘥 𝘨𝘶𝘪𝘥𝘦 𝘵𝘩𝘦 𝘧𝘶𝘵𝘶𝘳𝘦 𝘰𝘧 𝘱𝘳𝘰𝘵𝘰𝘯 𝘵𝘩𝘦𝘳𝘢𝘱𝘺 𝘪𝘯 𝘓𝘢𝘵𝘪𝘯 𝘈𝘮𝘦𝘳𝘪𝘤𝘢.”

👉 Read the full press release here: https://www.iba-worldwide.com/iba-install-first-proton-therapy-center-brazil-rio-de-janeiro

*Image for illustrative purposes only

08/06/2026

We are delighted to announce the signing of a contract with Duke University Health System for the installation of two Proteus®ONE compact proton therapy solutions at the Duke Proton Center in Durham, NC, USA.

The two Proteus®ONE systems will be installed side by side in a configuration designed to maximize clinical availability, operational flexibility, and patient treatment efficiency.

Prof. Erik Sulman, MD, Chair of the Department of Radiation Oncology and Interim Executive Director, Duke Cancer Institute, added: “Duke Health is taking an important step toward transforming cancer care across our state. By developing a proton therapy center, we can offer one of the most precise treatments available, helping patients achieve better outcomes with fewer side effects closer to home.”

👉 Read the full press release here: https://www.iba-worldwide.com/iba-signs-contract-major-us-academic-medical-center-install-two-proteusrone-proton-therapy

13/05/2026

We are proud to announce the introduction of 𝐀𝐝𝐚𝐏𝐓𝐢𝐧𝐬𝐢𝐠𝐡𝐭 𝐗𝐑, the next generation of CBCT imaging for image-guided proton therapy.
Building on the existing AdaPTinsight solution, AdaPTinsight XR* helps clinicians 𝗿𝗲𝗱𝘂𝗰𝗲 𝗮𝗺𝗯𝗶𝗴𝘂𝗶𝘁𝘆 𝗶𝗻 𝗱𝗮𝗶𝗹𝘆 𝗮𝘀𝘀𝗲𝘀𝘀𝗺𝗲𝗻𝘁𝘀 𝗮𝗻𝗱 𝗳𝘂𝗹𝗹𝘆 𝗹𝗲𝘃𝗲𝗿𝗮𝗴𝗲 𝘁𝗵𝗲 𝗽𝗿𝗲𝗰𝗶𝘀𝗶𝗼𝗻 𝗽𝗼𝘁𝗲𝗻𝘁𝗶𝗮𝗹 𝗼𝗳 𝗣𝗿𝗼𝘁𝗲𝘂𝘀® 𝘀𝘆𝘀𝘁𝗲𝗺𝘀. Reinforcing clarity, confidence, and upgradeability, the solution strengthens IBA’s commitment to continuously advancing imaging performance across both installed and future proton therapy systems, making proton therapy more accessible and helping it become the standard of care for more cancer indications.

*The AdaPTinsight XR feature is the latest IBA CBCT solution for IGPT in development phase. IBA reserves the right to make changes in design, technical descriptions, and specifications of its products without prior notice. AdaPTinsight XR is planned as an upgrade to the existing AdaPTinsight feature, with availability depending on market, Proteus configuration, and applicable regulatory clearances.

👉 Read the full press release: https://www.iba-worldwide.com/iba-introduces-adaptinsight-xr-next-generation-cbct-imaging-image-guided-proton-therapy

27/03/2026

𝗥𝗲𝗰𝗼𝗿𝗱 𝗿𝗲𝘃𝗲𝗻𝘂𝗲 𝗮𝗻𝗱 𝗶𝗺𝗽𝗿𝗼𝘃𝗲𝗱 𝗽𝗿𝗼𝗳𝗶𝘁𝗮𝗯𝗶𝗹𝗶𝘁𝘆 𝗶𝗻 𝟮𝟬𝟮𝟱 𝗳𝗼𝗿 𝗜𝗕𝗔. Momentum across core businesses is robust, supported by progress in Proton Therapy and growing engagement in nuclear medicine.
👉 Read the full press release: https://www.iba-worldwide.com/iba-delivers-strong-fy-2025-results-solid-ex*****on-all-segments

📢 Press release

IBA delivers strong full-year results for 2025 with solid ex*****on in all segments.

Olivier Legrain, Chief Executive Officer of IBA, commented: "2025 marked a year of strong ex*****on for IBA, with a record revenue and improved profitability, enabling us to deliver on our guidance. Momentum across our core businesses is robust, supported by progress in Proton Therapy and growing engagement in nuclear medicine. With a strengthened financial structure and increased visibility on future activity, we are well positioned to continue executing our strategy with confidence."

🔗 Read the full press release here: https://www.iba-worldwide.com/iba-delivers-strong-fy-2025-results-solid-ex*****on-all-segments

08/03/2026

04/02/2026

🎗️ Today, on World Cancer Day, we are joining the “Cancer Turned My World Upside Down” challenge, and we remain committed to offering proton therapy to all who could benefit from it.

27/01/2026

Our commercial kickoff in beautiful Mechelen, Belgium, has just come to a close. And what an inspiring few days!
It was a valuable moment to exchange perspectives, strengthen our shared direction, and set priorities for the months ahead.
With a clear focus on impact, we continue to work toward one ambition: expanding access to proton therapy and helping more patients worldwide benefit from it.

27/01/2026

🎉We are thrilled to share that we have signed 𝗮 𝗰𝗼𝗻𝘁𝗿𝗮𝗰𝘁 𝗳𝗼𝗿 𝗮 𝗣𝗿𝗼𝘁𝗲𝘂𝘀𝗢𝗡𝗘 𝗽𝗿𝗼𝘁𝗼𝗻 𝘁𝗵𝗲𝗿𝗮𝗽𝘆 𝘀𝘆𝘀𝘁𝗲𝗺 𝘁𝗼 MACKAY MEMORIAL HOSPITAL 𝗶𝗻 𝗡𝗲𝘄 𝗧𝗮𝗶𝗽𝗲𝗶 𝗖𝗶𝘁𝘆, 𝗧𝗮𝗶𝘄𝗮𝗻.

Dr. Chun-Hao Chen, MD, PhD, Director of the Department of Radiation Oncology at MacKay Memorial Hospital, stated:
“𝘞𝘦 𝘢𝘳𝘦 𝘱𝘳𝘰𝘶𝘥 𝘵𝘰 𝘱𝘢𝘳𝘵𝘯𝘦𝘳 𝘸𝘪𝘵𝘩 𝘐𝘉𝘈 𝘵𝘰 𝘣𝘳𝘪𝘯𝘨 𝘵𝘩𝘪𝘴 𝘢𝘥𝘷𝘢𝘯𝘤𝘦𝘥 𝘵𝘦𝘤𝘩𝘯𝘰𝘭𝘰𝘨𝘺 𝘵𝘰 𝘛𝘢𝘪𝘸𝘢𝘯. 𝘛𝘩𝘦 𝘪𝘯𝘴𝘵𝘢𝘭𝘭𝘢𝘵𝘪𝘰𝘯 𝘰𝘧 𝘵𝘩𝘦 𝘗𝘳𝘰𝘵𝘦𝘶𝘴®𝘖𝘕𝘌 𝘴𝘺𝘴𝘵𝘦𝘮 𝘢𝘵 𝘔𝘢𝘤𝘒𝘢𝘺 𝘔𝘦𝘮𝘰𝘳𝘪𝘢𝘭 𝘏𝘰𝘴𝘱𝘪𝘵𝘢𝘭 𝘸𝘪𝘭𝘭 𝘴𝘪𝘨𝘯𝘪𝘧𝘪𝘤𝘢𝘯𝘵𝘭𝘺 𝘦𝘯𝘩𝘢𝘯𝘤𝘦 𝘰𝘶𝘳 𝘢𝘣𝘪𝘭𝘪𝘵𝘺 𝘵𝘰 𝘱𝘳𝘰𝘷𝘪𝘥𝘦 𝘴𝘵𝘢𝘵𝘦-𝘰𝘧-𝘵𝘩𝘦-𝘢𝘳𝘵 𝘤𝘢𝘯𝘤𝘦𝘳 𝘵𝘳𝘦𝘢𝘵𝘮𝘦𝘯𝘵 𝘵𝘰 𝘰𝘶𝘳 𝘱𝘢𝘵𝘪𝘦𝘯𝘵𝘴. 𝘛𝘩𝘪𝘴 𝘤𝘰𝘭𝘭𝘢𝘣𝘰𝘳𝘢𝘵𝘪𝘰𝘯 𝘮𝘢𝘳𝘬𝘴 𝘢 𝘮𝘢𝘫𝘰𝘳 𝘮𝘪𝘭𝘦𝘴𝘵𝘰𝘯𝘦 𝘪𝘯 𝘰𝘶𝘳 𝘤𝘰𝘮𝘮𝘪𝘵𝘮𝘦𝘯𝘵 𝘵𝘰 𝘥𝘦𝘭𝘪𝘷𝘦𝘳𝘪𝘯𝘨 𝘸𝘰𝘳𝘭𝘥-𝘤𝘭𝘢𝘴𝘴 𝘤𝘢𝘳𝘦 𝘢𝘯𝘥 𝘦𝘹𝘱𝘢𝘯𝘥𝘪𝘯𝘨 𝘢𝘤𝘤𝘦𝘴𝘴 𝘵𝘰 𝘪𝘯𝘯𝘰𝘷𝘢𝘵𝘪𝘷𝘦 𝘵𝘩𝘦𝘳𝘢𝘱𝘪𝘦𝘴 𝘧𝘰𝘳 𝘵𝘩𝘦 𝘭𝘰𝘤𝘢𝘭 𝘤𝘰𝘮𝘮𝘶𝘯𝘪𝘵𝘺.”

This is 𝘁𝗵𝗲 𝗳𝗼𝘂𝗿𝘁𝗵 𝗼𝗿𝗱𝗲𝗿 𝗼𝗳 𝗮 𝗣𝗿𝗼𝘁𝗲𝘂𝘀𝗢𝗡𝗘 𝘀𝘆𝘀𝘁𝗲𝗺 𝗶𝗻 𝗧𝗮𝗶𝘄𝗮𝗻, further reinforcing IBA’s position as the undisputed market leader.

👉 Read the full press release here: https://www.iba-worldwide.com/iba-signs-contract-proteusrone-proton-therapy-system-be-located-mackay-memorial-hospital-new-taipei

27/12/2025

🎉🎉🎉Honored and excited to announce that 𝘄𝗲 𝗵𝗮𝘃𝗲 𝘀𝗶𝗴𝗻𝗲𝗱 𝗮 𝗰𝗼𝗻𝘁𝗿𝗮𝗰𝘁 with 𝗧𝗵𝗲 𝗖𝗮𝘁𝗵𝗼𝗹𝗶𝗰 𝗨𝗻𝗶𝘃𝗲𝗿𝘀𝗶𝘁𝘆 𝗼𝗳 𝗞𝗼𝗿𝗲𝗮, 𝗦𝗲𝗼𝘂𝗹 𝗦𝘁. 𝗠𝗮𝗿𝘆'𝘀 𝗛𝗼𝘀𝗽𝗶𝘁𝗮𝗹, one of South Korea’s largest hospitals!
This agreement includes the installation of a 𝗣𝗿𝗼𝘁𝗲𝘂𝘀®𝗣𝗟𝗨𝗦 solution with 𝘁𝗵𝗿𝗲𝗲 𝗴𝗮𝗻𝘁𝗿𝘆 𝗿𝗼𝗼𝗺𝘀. The system will also include 𝗗𝘆𝗻𝗮𝗺𝗶𝗰𝗔𝗥𝗖®* beam delivery capabilities.
Seoul St. Mary’s Hospital plans to 𝗯𝗲𝗴𝗶𝗻 𝗽𝗮𝘁𝗶𝗲𝗻𝘁 𝘁𝗿𝗲𝗮𝘁𝗺𝗲𝗻𝘁𝘀 𝗯𝘆 𝘁𝗵𝗲 𝗲𝗻𝗱 𝗼𝗳 𝟮𝟬𝟮𝟵.

👉 Read the full press release: https://www.iba-worldwide.com/iba-signs-contract-three-room-proteusrplus-solution-be-installed-seoul-st-marys-hospital

*DynamicARC® is a registered brand of the IBA’s Proton Arc therapy solution currently under development phase.

19/12/2025

Wishing you happy holidays and a wonderful end of year from all of us at IBA Proton Therapy. ✨